The life settlement’s secondary market sees significant deal flow from advisors such as attorneys, CPAs and financial planners. Greg Winterton caught up with Brandon Marz, Co-Founder and Chief Strategy Officer at LifeRoc Capital, to get his thoughts on the ‘state of the market’ for this cohort as it pertains to life settlements in this month’s Q&A.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Post a comment
Related Posts
Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet
A new report by reinsurer RGA says that the combination of disease-modifying therapies and better…
EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper
Feedback from the industry is due by the end of April.
Better Mortality Analytics Will Unlock the Next Phase of Life Settlement Growth
How durational mortality curves, stochastic A/E analysis and independent audits can strengthen investor confidence and…
Is the Secondary Life Insurance Market in the UK Set To Re-Emerge?
Why a different approach might be needed to bring the UK’s secondary life insurance market…
